Ibogaine

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcAscending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients
3. 2026-09-24srcAscending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability
4. 2026-09-24srcInfluence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers
5. 2026-09-24srchERG Blockade by Iboga Alkaloids
6. 2026-09-24srcAnti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
7. 2026-09-24srcMystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans
8. 2026-09-24srcEffects of low dose ibogaine on subjective mood state and psychological performance
9. 2026-09-24srcA systematic literature review of clinical trials and therapeutic applications of ibogaine
10. 2026-09-24srcThe therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies
11. 2026-09-24srcEfficient Access to the Iboga Skeleton: Optimized Procedure to Obtain Voacangine from Voacanga africana Root Bark
12. 2026-09-24srcOxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models
13. 2026-09-24srcMagnesium-ibogaine therapy in veterans with traumatic brain injuries
14. 2026-09-24srcIbogaine and addiction in the animal model, a systematic review and meta-analysis
15. 2026-09-24srcToxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine
16. 2026-09-24srcPsychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine
17. 2026-09-24srcSafety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study
18. 2026-09-24srcNoribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration
19. 2026-09-24srcThe pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
20. 2026-09-24srcIbogaine, an anti-addictive drug: pharmacology and time to go further in development
21. 2026-09-24srcEffect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation
22. 2026-09-24srcIbogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature
23. 2026-09-24srcHow toxic is ibogaine?
24. 2026-09-24srcIbogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence
25. 2026-09-24srcDrug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
26. 2026-09-24srcIbogaine's potential role in supporting reward system recovery across diagnostic boundaries
27. 2026-09-24srcThe anti-addiction drug ibogaine and the heart: a delicate relation
28. 2026-09-24srcTreatment of acute opioid withdrawal with ibogaine
29. 2026-09-24srcDevelopment of novel medications for drug addiction. The legacy of an African shrub
30. 2026-09-24srcA dose-response study of ibogaine-induced neuropathology in the rat cerebellum
31. 2026-09-24src18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action
32. 2026-09-24srcMechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener
33. 2026-09-24srcMechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies
34. 2026-09-24srcGlial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption
35. 2026-09-24srcReceptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity
36. 2026-09-24srcIbogaine block of the NMDA receptor: in vitro and in vivo studies
37. 2026-09-24srcIbogaine neurotoxicity: a re-evaluation
38. 2026-09-24srcIbogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors
39. 2026-09-24srcEvidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine
40. 2026-09-24srcThe olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells
41. 2026-09-24srcMechanisms of antiaddictive actions of ibogaine
42. 2026-09-24srcIbogaine legal status and scheduling history
43. 2026-09-24srcState-by-State Ibogaine Legislation tracker
44. 2026-09-04issueIssued emergency
45. 2026-09-04issueIssued info_card
46. 2026-09-04issueIssued notice
47. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
48. 2026-06-04publicationPublication — backfill
49. 2026-04-26revisionRevision 1
50. 2026-04-26absenceSearched web for "ibogaine physical properties CAS LD50" — no results
51. 2026-04-26absenceSearched PubMed for "ibogaine LD50 lethal dose toxicity animal" — no results
52. 2026-04-26absenceSearched PubChem web for "ibogaine CAS melting point logP LD50" — no results
53. 2026-04-26absenceSearched PubMed for "ibogaine LD50 lethal dose toxicity animal study mouse rat" — no results
54. 2026-04-26genGeneration — pipeline-v5pipeline-v5
55. 2026-04-26rungeneration run

The same entries, as forms: six forms.